NeuroScientific Biopharmaceuticals Ltd. announced the recruitment of the first subject in its early-phase clinical trial for its lead drug candidate EmtinB, achieving a significant milestone in the development of EmtinB as a first-in-class treatment with disease modifying potential for neurodegenerative conditions, such as Multiple sclerosis and Alzheimer's disease. The early-phase clinical trial is being undertaken by leading WA-based clinical research partner Linear Clinical Research.
NeuroScientific Biopharmaceuticals Limited
Equities
NSB
AU0000012973
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.052 AUD | +8.33% | 0.00% | +18.18% |
1st Jan change | Capi. | |
---|---|---|
+18.18% | 4.53M | |
+1.89% | 42.75B | |
+47.64% | 41.61B | |
+11.49% | 41.34B | |
-12.36% | 26.59B | |
+7.92% | 25.49B | |
-23.94% | 18.12B | |
+29.58% | 12.24B | |
-1.96% | 11.76B | |
+7.69% | 11B |
- Stock Market
- Equities
- NSB Stock
- News NeuroScientific Biopharmaceuticals Limited
- NeuroScientific Biopharmaceuticals Limited Announces Recruitment of First Subject Recruited for Early-Phase Clinical Trial